Catalent has agreed to acquire a major stake in privately owned Zhejiang Jiang Yuan Tang Biotechnology, which manufactures nutritional softgel products for Chinese and Asia Pacific markets.
The US-based company and ShangPharma have agreed to form Catalent (Shanghai) Clinical Trial Supplies to offer end-to-end solutions for clinical trial supplies, including comparator sourcing, primary and secondary packaging and labeling, as well as storage and distribution.
Catalent also plans to make additional investments in these two facilities over the next several years to expand its services in the Chinese market.
Catalent president and CEO John Chiminski said, "As part of the growth strategy, these initiatives enable the company to better serve the important Chinese market for both global and domestic customers".
"Our clients and their patients will benefit from access to Catalent’s advanced technologies and solutions, together with best-in-class innovation, reliable supply and quality compliance," Chiminski added.